Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1838-1846

  Zecca, Marco ^a   Pession, Andrea ^a   Messina, Chiara ^a   Bonetti, Federico ^a   Favre, Claudio ^a   Prete, Arcangelo ^a   Cesaro, Simone ^a   Porta, Fulvio ^a   Mazzarino, Ida ^a   Giorgiani, Giovanna ^a   Rondelli, Roberto ^a   Locatelli, Franco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; THIOTEPA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MALE; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; REMISSION; SKIN TOXICITY; WHOLE BODY RADIATION;

EID: 0033032640     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1838     Document Type: Article

References (52)

1. Poplack DG: Acute lymphoblastic leukemia, in Pizzo AP, Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia, PA, JB Lippincott Company, 1989, pp 323-366
2. Ritter J, Creutzig U, Reiter A, et al: Childhood leukemia: Cooperative Berlin-Frankfurt-Munster trials in the Federal Republic of Germany. J Cancer Res Clin Oncol 116:100-103, 1990
3. Schorin MA, Blattner S, Gelber RD, et al: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/ Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740-747, 1994
4. Rivera GK, Pinkel D, Simone JV, et al: Treatment of acute lymphoblastic leukemia: 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 329:1289-1295, 1993
5. Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998
6. Pui C-H, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 339:605-615, 1998
7. Gratwohl A, Hermans J, Baldomero H, et al: Indications for haemopoietic precursor cell transplants in Europe: European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 92:35-43, 1996
8. Ramsay NKC, Kersey JH: Indications for marrow transplantation in acute lymphoblastic leukemia. Blood 75:815-818, 1990
9. Goldman JM, Schmitz N, Niethammer D, et al: Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe in 1998. Bone Marrow Transplant 21:1 -7, 1998
10. Gratwohl A, Hermans J, Baldomero H: Blood and marrow transplantation activity in Europe 1995: European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 19:407-419, 1997
11. Barrett AJ, Horowitz MM, Pollock BH, et al: Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in second remission. N Engl J Med 331:1253-1258, 1994
12. Uderzo C, Valsecchi MG, Balduzzi A, et al: Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. Br J Haematol 96:387-394, 1997
13. Dopfer R, Henze C, Bender-Götze C, et al: Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM-and CoALL-protocols: Results of the German cooperative study. Blood 78:2780-2784, 1998
14. Deconinck E, Cahn JY, Milpied N, et al: Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: Long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan). Bone Marrow Transplant 20:731-735, 1997
15. Feig SA, Harris RE, Sather HN: Bone marrow transplantation versus chemotherapy for maintenance of second remission of childhood acute lymphoblastic leukemia: A study of the Children's Cancer Group (CCG-1884). Med Pediatr Oncol 29:534-540, 1997
16. Carpenter PA, Marshall GM, Giri N, et al: Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan. Bone Marrow Transplant 18:489-494, 1996
17. Uderzo C, Rondelli R, Dini G, et al: High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: A 7-year Italian multicentre study. Br J Haematol 89:790-797, 1995
18. von Bueltzingsloewen A, Belanger R, Perreault C, et al: Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia. Br J Haematol 85:706-713, 1993
19. Down JD, Westerhof GR, Boudewijn A, et al: Thiotepa improves allogeneic bone marrow engraftment without ennhancing stem cell depletion in irradiated mice. Bone Marrow Transplant 21:327-330, 1998
20. Terenzi A, Lubin I, Lapidot T, et al: Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. Transplantation 50:717-720, 1990
21. Rigden JP, Cornetta K, Srour EF, et al: Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation. Bone Marrow Transplant 18:913-919, 1996
22. Wolff SN, Herzig RH, Fay JW, et al: High-dose N, N′, N″-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies. Semin Oncol 17:2-6, 1990
23. Przepiorka D, Dimopoulos M, Smith T, et al: Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicity. Ann Hematol 68:183-188, 1994
24. Przepiorka D, Ippoliti C, Giralt S, et al: A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 14:449-453, 1994
25. Kamani N, August CS, Bunin N, et al: A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant 17:911-916, 1996
26. Vecchi V, Pession A, Rosati D, et al: Childhood acute lymphoblastic leukemia (ALL): Results of AIEOP 87 protocol generation. Med Pediatr Oncol 20:390, 1992 (abstr)
27. Conter V, Aricò M, Valsecchi MG, et al: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in intermediate risk ALL children treated with BFM-based intensive chemotherapy. J Clin Oncol 13:2497-2502, 1995
28. Conter V, Aricò M, Valsecchi MG, et al: Intensive BFM chemotherapy for childhood ALL: Interim analysis of the AIEOP-ALL 91 study. Haematologica 83:791-799, 1998
29. Pui C-H: Childhood leukemias. N Engl J Med 332:1618-1630, 1995
30. Gaynon PS, Bleyer WA, Steinherz PG, et al: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273-279, 1990
31. Reiter A, Schrappe M, Ludwig W-D, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
32. Fletcher JA, Lynch EA, Kimball VM, et al: Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 77:435-439, 1991
33. Schrappe M, Aricò M, Harbott J, et al: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood 92:2730-2741, 1998
34. Glucksberg H, Storb R, Fefer A, et al: Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295-304, 1974
35. Shulman HM, Sullivan KM, Weiden PL, et al: Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204-217, 1980
36. Bearman SI, Appelbaum FR, Back A, et al: Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 7:1288-1294, 1989
37. Bearman SI, Appelbaum FR, Buckner CD, et al: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1988
38. Kaplan EL, Meyer P: Nonparametral estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
39. Locatelli F, Uderzo C, Dini G, et al: Graft-versus-host disease in children: The AIEOP-BMT Group experience with cyclosporin A. Bone Marrow Transplant 12:627-633, 1993
40. Barrett AJ, van Rhee F: Graft-versus-leukaemia. Baillieres Clin Haematol 10:337-355, 1997
41. Moussalem M, Esperou Bourdeau H, Devergie A, et al: Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: Factors predictive of survival, relapse and graft-versus-host disease. Bone Marrow Transplant 15:943-947, 1995
42. Coccia PF, Strandjord SE, Warkentin PI, et al: High-dose cytosine arabinoside and fractionated total-body irradiation: An improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood 71:888-893, 1988
43. Brochstein JA, Kernan NA, Groshen S, et al: Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 317:1618-1624, 1987
44. Blume KG, Forman SJ, O'Donnell MR, et al: Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015-1020, 1987
45. Bordigoni P, Esperou H, Souillet G, et al: Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Graffe de Moelle study. Br J Haematol 102:656-665, 1998
46. Papadopoulos EB, Carabasi MH, Castro Malaspina H, et al: T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease. Blood 91:1083-1090, 1998
47. Henze G, Fengler R, Hartmann R, et al: Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): A relapse study of the BFM Group. Blood 78:1166-1172, 1991
48. Chessells JM, Bailey C, Wheeler K, et al: Bone marrow transplantation for high-risk childhood leukaemia in first remission: Experience in MRC UKALL X. Lancet 340:565-568, 1992
49. Saarinen UM, Mellander L, Nysom K, et al: Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: A retrospective case-control study in the Nordic countries. Bone Marrow Transplant 17:357-363, 1996
50. Bordigoni P, Vernant JP, Souillet G, et al: Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: A cooperative study of the Groupe d'Etude de la Greffe de Moelle Osseuse. J Clin Oncol 7:747-753, 1989
51. Uderzo C, Valsecchi MG, Bacigalupo A, et al: Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: Ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 13:352-358, 1995
52. O'Dwyer PJ, La Creta F, Engstrom PF, et al: Phase I/pharmacokinetic reevaluation of thioTEPA. Cancer Res 51:3171-3176, 1991